Incyte Corporation

NasdaqGS:INCY Stock Report

Market Cap: US$19.9b

Incyte Management

Management criteria checks 2/4

We currently do not have sufficient information about the CEO.

Key information

Bill Meury

Chief executive officer

n/a

Total compensation

CEO salary percentagen/a
CEO tenureless than a year
CEO ownershipn/a
Management average tenure3.3yrs
Board average tenure6.1yrs

Recent management updates

Recent updates

Tracking Baker Brothers Portfolio - Q3 2025 Update

Dec 16

Results: Incyte Corporation Beat Earnings Expectations And Analysts Now Have New Forecasts

Oct 31
Results: Incyte Corporation Beat Earnings Expectations And Analysts Now Have New Forecasts

Incyte Corporation's (NASDAQ:INCY) Price Is Right But Growth Is Lacking After Shares Rocket 26%

Aug 14
Incyte Corporation's (NASDAQ:INCY) Price Is Right But Growth Is Lacking After Shares Rocket 26%

Additional Considerations Required While Assessing Incyte's (NASDAQ:INCY) Strong Earnings

Aug 06
Additional Considerations Required While Assessing Incyte's (NASDAQ:INCY) Strong Earnings

Investors Aren't Buying Incyte Corporation's (NASDAQ:INCY) Revenues

Apr 30
Investors Aren't Buying Incyte Corporation's (NASDAQ:INCY) Revenues

Incyte: Still A 'Buy' Despite HS Treatment Data With Povorcitinib

Mar 18

Incyte: Q4 Earnings Outlines Multiple Drug Launches In 2025

Feb 11

Incyte: Multiple Drug Launches Bode Well For Future Growth

Jan 11

Incyte: Q3 Earnings Ramping Up Growth To Jump The Patent Cliff

Oct 31
User avatar

Tactical Expansions And First-in-Class Molecules Set To Propel Growth In High-Need Medical Areas

Incyte's focus on expanding its clinical pipeline with first-in-class molecules and novel therapies aims to drive growth by increasing market share and revenue.

Incyte: Monjuvi Advancement Continues With Positive FL Treatment Data

Aug 19

CEO

Bill Meury (57 yo)

less than a year
Tenure

Mr. William Meury, also known as Bill, is Director of Uniquity Bio, Inc. Mr. Meury served as the Chief Executive Officer & Director of Anthos Therapeutics, Inc. since April 2024. He is CEO, President & Dir...

Leadership Team

NamePositionTenureCompensationOwnership
Pablo Cagnoni
President and Head of Research & Development2.7yrsUS$7.90m0.0026%
$ 521.7k
Steven Stein
Executive VP & Chief Medical Officer10.8yrsUS$5.98m0%
$ 0
William Meury
CEO, President & Directorless than a yearno datano data
Thomas Tray
Principal Financial Officer3.8yrsno data0.0040%
$ 792.5k
Michael Morrissey
Executive VP & Head of Global Technical Operations10yrsno data0%
$ 0
Alexis Smith
Vice President & Head of Investor Relationsno datano datano data
Richard Hoffman
Executive VP & General Counselless than a yearno datano data
Pamela Murphy
Vice President of Investor Relations & Corporate Communicationsno datano datano data
Soni Basi
Executive VP & Chief Human Resources Officerless than a yearno datano data
Vijay Iyengar
Executive Officerno dataUS$3.30m0.0014%
$ 282.7k
James Lee
Group VPno datano datano data
Denise Brashear
VP & Head of Global Communications4yrsno datano data
3.3yrs
Average Tenure
58yo
Average Age

Experienced Management: INCY's management team is considered experienced (3.3 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
William Meury
CEO, President & Directorless than a yearno datano data
Jean-Jacques Bienaime
Independent Director11yrsUS$518.15k0.0093%
$ 1.9m
Julian Baker
Independent Chairman of the Board24.2yrsUS$552.15k0.14%
$ 28.3m
Otis Brawley
Independent Director4.3yrsUS$494.15k0.0044%
$ 886.0k
Jacqualyn Fouse
Independent Director9yrsUS$505.65k0.0086%
$ 1.7m
Edmund Harrigan
Independent Director6.1yrsUS$521.65k0.0092%
$ 1.8m
Katherine High
Independent Director5.8yrsUS$494.15k0.0055%
$ 1.1m
Paul Clancy
Independent Director11yrsUS$519.15k0.011%
$ 2.1m
Susanne Schaffert
Independent Director3.3yrsUS$503.88k0.0025%
$ 493.8k
6.1yrs
Average Tenure
64yo
Average Age

Experienced Board: INCY's board of directors are considered experienced (6.1 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/01/04 19:32
End of Day Share Price 2026/01/02 00:00
Earnings2025/09/30
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Incyte Corporation is covered by 52 analysts. 20 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Jasper HellwegArgus Research Company
Thomas RussoBaird
Ying HuangBarclays